Klamath Promise

Klamath Therapeutics is a pre-clinical stage biotechnology company focused on the development of novel small molecule therapeutics targeting mitochondrial metabolism. Founded by leading scientists from the Buck Institute for Research on Aging, the company aims to exploit metabolic dependencies in cancer cells and address mitochondrial dysfunction in age-related pathologies. Klamath is backed by prominent venture capital firms, including The Column Group, and operates out of San Francisco. The company's research leverages a deep understanding of mitochondrial biology to identify and inhibit specific metabolic pathways that drive disease progression.